Multi-step virtual screening to develop selective DYRK1A inhibitors

被引:11
|
作者
Koyama, Tomoko [1 ]
Yamaotsu, Noriyuki [1 ]
Nakagome, Izumi [1 ]
Ozawa, Shin-ichiro [1 ]
Yoshida, Tomoki [1 ]
Hayakawa, Daichi [1 ]
Hirono, Shuichi [1 ]
机构
[1] Kitasato Univ, Sch Pharm, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan
来源
JOURNAL OF MOLECULAR GRAPHICS & MODELLING | 2017年 / 72卷
关键词
DYRK1A; Kinase selectivity; In silico screening; Free energy decomposition; Discriminant analysis; FORCE-FIELD; BINDING; KINASES; ANALOGS; DESIGN; REGULARIZATION; SIMULATIONS; ACTIVATION; SCAFFOLDS; COUMARINS;
D O I
10.1016/j.jmgm.2017.01.014
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Developing selective inhibitors for a particular kinase remains a major challenge in kinase-targeted drug discovery. Here we performed a multi-step virtual screening for dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors by focusing on the selectivity for DYRK1A over cyclin-dependent kinase 5 (CDK5). To examine the key factors contributing to the selectivity, we constructed logistic regression models to discriminate between actives and inactives for DYRK1A and CDK5, respectively, using residue-based binding free energies. The residue-based parameters were calculated by molecular mechanics-generalized Born surface area (MM-GBSA) decomposition methods for kinase-ligand complexes modeled by computer ligand docking. Based on the findings from the logistic regression models, we built a three-dimensional (3D) pharmacophore model and chose filter criteria for the multi-step virtual screening. The virtual hit compounds obtained from the screening were assessed for their inhibitory activities against DYRK1A and CDK5 by in vitro assay. Our screening identified two novel selective DYRK1A inhibitors with IC50 values of several mu M for DYRK1A and >100 mu M for CDK5, which can be further optimized to develop more potent selective DYRK1A inhibitors. (C) 2017 Elsevier Inc.
引用
收藏
页码:229 / 239
页数:11
相关论文
共 50 条
  • [21] Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B
    Segretti, Natanael D.
    Takarada, Jessica E.
    Ferreira, Marcos A., Jr.
    Santiago, Andre da Silva
    Teodoro, Bruno V. M.
    Damiao, Mariana C. F. C. B.
    Godoi, Paulo H.
    Cunha, Micael R.
    Fala, Angela M.
    Ramos, Priscila Z.
    Ishikawa, Eloisa E.
    Mascarello, Alessandra
    Serafim, Ricardo A. M.
    Azevedo, Hatylas
    Guimaraes, Cristiano R. W.
    Counago, Rafael M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 68
  • [22] Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches
    Yoon, Hye Ree
    Balupuri, Anand
    Choi, Kwang-Eun
    Kang, Nam Sook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 12
  • [23] Development of novel DYRK1A inhibitors for the treatment of Alzheimer's disease
    HuangFu, W.
    Tu, H.
    Peng, Z.
    Su, C.
    FEBS OPEN BIO, 2019, 9 : 227 - 228
  • [24] DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
    Barzowska, Agata
    Pucelik, Barbara
    Pustelny, Katarzyna
    Matsuda, Alex
    Martyniak, Alicja
    Stepniewski, Jacek
    Maksymiuk, Anna
    Dawidowski, Maciej
    Rothweiler, Ulli
    Dulak, Jozef
    Dubin, Grzegorz
    Czarna, Anna
    CELLS, 2021, 10 (09)
  • [25] Selective inhibition of the kinase DYRK1A by targeting its folding process
    Kii, Isao
    Sumida, Yuto
    Goto, Toshiyasu
    Sonamoto, Rie
    Okuno, Yukiko
    Yoshida, Suguru
    Kato-Sumida, Tomoe
    Koike, Yuka
    Abe, Minako
    Nonaka, Yosuke
    Ikura, Teikichi
    Ito, Nobutoshi
    Shibuya, Hiroshi
    Hosoya, Takamitsu
    Hagiwara, Masatoshi
    NATURE COMMUNICATIONS, 2016, 7
  • [26] Selective inhibition of the kinase DYRK1A by targeting its folding process
    Isao Kii
    Yuto Sumida
    Toshiyasu Goto
    Rie Sonamoto
    Yukiko Okuno
    Suguru Yoshida
    Tomoe Kato-Sumida
    Yuka Koike
    Minako Abe
    Yosuke Nonaka
    Teikichi Ikura
    Nobutoshi Ito
    Hiroshi Shibuya
    Takamitsu Hosoya
    Masatoshi Hagiwara
    Nature Communications, 7
  • [27] Discovery of DYRK1A inhibitors as potential treatment of pancreatic ductal adenocarcinoma (PDAC)
    Hsieh, Hsing-Pang
    Zhang-Jian, Yu-Xiang
    Hsu, Kai-Cheng
    Pan, Shiow-Lin
    Li, Wen-Shan
    Wu, Han-Chung
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 116 - 116
  • [28] Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease
    Warren, Hunter T.
    Saeger, Hannah N.
    Tombari, Robert J.
    Chytil, Milan
    Rasmussen, Kurt
    Olson, David. E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (09) : 6922 - 6937
  • [29] Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors
    Drung, Binia
    Scholz, Christoph
    Barbosa, Valeria A.
    Nazari, Azadeh
    Sarragiotto, Maria H.
    Schmidt, Boris
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (20) : 4854 - 4860
  • [30] Discovery of 3-hydroxy-3-pyrrolin-2-one-based mPGES-1 inhibitors using a multi-step virtual screening protocol
    Lauro, Gianluigi
    Cantone, Vincenza
    Potenza, Marianna
    Fischer, Katrin
    Koeberle, Andreas
    Werz, Oliver
    Riccio, Raffaele
    Bifulco, Giuseppe
    MEDCHEMCOMM, 2018, 9 (12) : 2028 - 2036